Nanchangmycin (Nam), a polyketide antibiotic, is identified to inhibit c-Maf activity in the presence of OTUB1, indicating that Nam has the potential to treat MM by targeting the OTUB1/c-Maf axis [147]. This evidence concerns the gene MAF and Miyoshi myopathy.